located in Baltimore, is focused on automated ultrasound solutions to quantify and visualize critical clinical data for surgeons who need reliable information on-demand. Gammie, who is Chief of Cardiac Surgery at UMD and introduced Dr. Sunjay Kaushal, M.D., Ph.D., Founder & Chief Medical Officer of NeoProgen is the Chief of Pediatric Cardiac Surgery at the University of Maryland Medical Center and works with Dr. NeoProgen anticipates that its first clinical trial will begin in 2020.ĭr. Niland, the company’s CEO, recently helped the company raise $1.5M in seed funding from the University of Maryland Momentum Fund, TEDCO and UM Ventures. NeoProgen, also located in Baltimore, is a pre-clinical therapeutics company developing a cell therapy for patients that have had a heart attack. The company anticipates starting its first clinical trial in 2020. The company closed on $2M in equity funding from TEDCO’s Maryland Venture Fund, the Abell Foundation and other angel investors in late 2018. The Baltimore-based medical device company is developing the next generation of minimally invasive spinal implants for lower back pain and degenerative disc disease. Gammie’s Cardiac department.įollowing the sale of Harpoon, Niland, one of the most successful BHCR serial entrepreneurs, has gone on to start and advise new companies to help move a number of innovative technologies toward commercialization. Six Maryland companies, including NeoProgen and Breethe, a Maryland company focused on developing and commercializing the next generation of artificial lungs for hospital and home use, have been spun out of Dr. Gammie has fostered a spirit of innovation within the Cardiac Surgery department of the University of Maryland Medical Center. However, the company’s influential founders are already making a strong impact on the region. Harpoon Medical’s legacy has a long way to go to match that of MedImmune. Former MedImmune employees went on to lead or found organizations like Sucampo Pharmaceuticals, MacroGenics, and Amplimmune, to name just a few. The MedImmune brand has since been retired, but the company’s success gave birth to numerous BHCR companies that have contributed and still contribute to the region’s growing reputation as a global biohealth cluster. Gamme have not stood pat instead, they’ve played instrumental roles in a number of new BHCR companies, proving once again, like we have seen through Human Genome Sciences, Life Tech and MedImmune before it, that success breeds success.ĪstraZeneca’s acquisition of MedImmune for $15.6B in 2007 was a landmark deal in the history of the region. Since the acquisition, serial entrepreneur Niland and Dr. While Harpoon Medical is now part of Edwards Lifesciences, the Baltimore company’s legacy is still reverberating throughout the BHCR. Gamme, and lead investor Epidarex Capital of Bethesda, Maryland, the Harpoon deal with Edwards Lifesciences was a remarkable, complex and hard-won agreement. For Harpoon’s founders Bill Nilandand Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |